{"schema_version":"secwatch.filing_event.v1","accession":"0001321732-24-000086","form_type":"8-K","ticker":"PEN","cik":"0001321732","company_name":"Penumbra Inc","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.581343+00:00","generated_at":"2026-05-31T15:04:17.900624+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Penumbra Q2 revenue $299.4M (+14.5%); loss from ops $81M on $110.3M impairment charges","bullets":["U.S. thrombectomy revenue $153.7M, up 24.9% YoY; global thrombectomy revenue $203.5M (+25.2%).","GAAP operating loss $81.0M includes $110.3M non-cash impairment/write-down on Immersive Healthcare assets.","Non-GAAP income from operations $31.7M vs $20.3M YoY; adjusted EBITDA $46.3M (15.5% margin).","Cash/marketable investments increased $26.2M from Q1, driven by non-GAAP profitability and working capital.","Global embolization & access revenue fell 3.1% YoY to $95.9M, with international down 10.8%."],"urls":{"canonical":"https://secwatch.observer/filing/0001321732-24-000086","json":"https://secwatch.observer/filing/0001321732-24-000086.json","markdown":"https://secwatch.observer/filing/0001321732-24-000086.md","text":"https://secwatch.observer/filing/0001321732-24-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321732/000132173224000086/0001321732-24-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321732/000132173224000086/pen-20240730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:04:17.900624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}